Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Berry Oncology has developed and commercialized the HIFI system for early multi-cancer screening. Clinical data show high sensitivity and specificity in liver and multiple other cancers. For liver cancer specifically, sensitivity reached 95.42% and specificity 97.91%; for six major tumor types combined (liver, lung, gastric, colorectal, esophageal & pancreatic), sensitivity was 87.58% with specificity of 99.09%. The company has completed large-scale prospective cohort studies in China and serves over 900 hospitals.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Berry Oncology.